Integer Holdings Co. (NYSE:ITGR) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its position in shares of Integer Holdings Co. (NYSE:ITGR) by 14.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,899 shares of the medical equipment provider’s stock after purchasing an additional 372 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Integer were worth $377,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its holdings in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 80 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its stake in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares during the last quarter. Innealta Capital LLC purchased a new stake in Integer in the 2nd quarter valued at $110,000. Finally, Hancock Whitney Corp acquired a new stake in shares of Integer in the 1st quarter worth $203,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Trading Down 1.2 %

Shares of NYSE:ITGR opened at $133.18 on Monday. The company has a market cap of $4.47 billion, a PE ratio of 41.10, a P/E/G ratio of 1.91 and a beta of 1.09. The company’s 50 day moving average is $129.20 and its two-hundred day moving average is $122.66. Integer Holdings Co. has a 52 week low of $84.75 and a 52 week high of $140.91. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The company had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. During the same period in the prior year, the firm posted $1.27 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. Equities analysts predict that Integer Holdings Co. will post 5.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ITGR has been the topic of several recent analyst reports. Truist Financial decreased their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a report on Friday, October 25th. KeyCorp raised their target price on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Piper Sandler reissued an “overweight” rating and set a $140.00 price objective (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Bank of America upped their target price on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Finally, Citigroup lifted their target price on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Integer currently has an average rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.